Compare Abeona Therapeutics Inc (ABEO) vs General Dynamics Corporation (GD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs General Dynamics Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while General Dynamics Corporation trades at $373.29 (market cap $101.31B). The key difference: General Dynamics Corporation is far larger — about 271.4× Abeona Therapeutics Inc's market cap, and General Dynamics Corporation pays a 1.7% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GD | |
|---|---|---|
Market Cap | $373.32M | $101.31B |
Sector | Health | Industrials |
52-Week High | $7.23 | $376.88 |
52-Week Low | $4.17 | $296.65 |
Enterprise Value | $228.22M | $107.49B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
General Dynamics (GD) trades at $374.64, up 0.29% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, while fundamentals are solid with revenue growth to $52.55 billion in 2025 and net income of $4.21 billion. Recent earnings beats and a massive $130.8 billion backlog support positive momentum, with analyst consensus leaning bullish.
Outlook remains favorable given defense budget tailwinds and execution strength, but valuation multiples like P/E of 23.72 suggest limited upside from current levels. Risks include contract execution delays and macroeconomic pressures. The stock offers steady growth and income via dividends, but investors should weigh rich valuations against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
